You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 9,809,559

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,809,559 protect, and when does it expire?

Patent 9,809,559 protects OJJAARA and is included in one NDA.

This patent has fifty-two patent family members in thirty-one countries.

Summary for Patent: 9,809,559

Patent landscape, scope, and claims:

Title:	(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Abstract:	The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
Inventor(s):	Brown Brandon H., Carra Ernest A., Hemenway Jeffrey N., Morrison Henry, Reynolds Troy, Shi Bing, Stefanidis Dimitrios, Wang Fang, Warr Matthew Robert, Whitney James Andrew, Xin Yan
Assignee:	GILEAD SCIENCES, INC.
Application Number:	US15231411
Patent Claim Types: see list of patent claims
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 9,809,559

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	OJJAARA	momelotinib dihydrochloride	TABLET;ORAL	216873-001	Sep 15, 2023		RX	Yes	No	9,809,559	⤷ Subscribe				FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS	⤷ Subscribe
Glaxosmithkline	OJJAARA	momelotinib dihydrochloride	TABLET;ORAL	216873-002	Sep 15, 2023		RX	Yes	No	9,809,559	⤷ Subscribe				FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS	⤷ Subscribe
Glaxosmithkline	OJJAARA	momelotinib dihydrochloride	TABLET;ORAL	216873-003	Sep 15, 2023		RX	Yes	Yes	9,809,559	⤷ Subscribe				FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,809,559

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	100818	⤷ Subscribe
Australia	2015274554	⤷ Subscribe
Brazil	112016028749	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.